vs
Arbutus Biopharma Corp（ABUS）与Foghorn Therapeutics Inc.（FHTX）财务数据对比。点击上方公司名可切换其他公司
Arbutus Biopharma Corp的季度营收约是Foghorn Therapeutics Inc.的1.2倍（$10.7M vs $9.2M），Arbutus Biopharma Corp净利率更高（23.5% vs -234.3%，领先257.8%），Arbutus Biopharma Corp同比增速更快（522.2% vs 223.8%），过去两年Foghorn Therapeutics Inc.的营收复合增速更高（35.3% vs -13.2%）
Arbutus生物制药是一家公开上市的加拿大生物制药企业，专长于脂质体药物递送与RNA干扰技术，目前主要开展针对乙型肝炎感染的治疗药物研发工作，在抗病毒新药研发领域拥有深厚的技术积累。
Foghorn Therapeutics是一家临床阶段生物技术企业，专注于开发靶向染色质调控系统的创新疗法，用于治疗多种癌症及其他严重疾病，目前推进多款靶向候选药物管线，通过自主研发与战略合作服务全球患者群体。
ABUS vs FHTX — 直观对比
营收规模更大
ABUS
是对方的1.2倍
$9.2M
营收增速更快
ABUS
高出298.4%
223.8%
净利率更高
ABUS
高出257.8%
-234.3%
两年增速更快
FHTX
近两年复合增速
-13.2%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $10.7M | $9.2M |
| 净利润 | $2.5M | $-21.7M |
| 毛利率 | — | — |
| 营业利润率 | 13.9% | -258.2% |
| 净利率 | 23.5% | -234.3% |
| 营收同比 | 522.2% | 223.8% |
| 净利润同比 | 112.7% | -11.1% |
| 每股收益（稀释后） | $0.01 | $-0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABUSFHTX
| Q4 25 | — | $9.2M | ||
| Q3 25 | — | $8.2M | ||
| Q2 25 | $10.7M | $7.6M | ||
| Q1 25 | — | $6.0M | ||
| Q4 24 | — | $2.9M | ||
| Q3 24 | — | $7.8M | ||
| Q2 24 | — | $6.9M | ||
| Q1 24 | — | $5.0M |
净利润ABUSFHTX
| Q4 25 | — | $-21.7M | ||
| Q3 25 | — | $-15.8M | ||
| Q2 25 | $2.5M | $-17.9M | ||
| Q1 25 | — | $-18.8M | ||
| Q4 24 | — | $-19.5M | ||
| Q3 24 | — | $-19.1M | ||
| Q2 24 | — | $-23.0M | ||
| Q1 24 | — | $-25.0M |
营业利润率ABUSFHTX
| Q4 25 | — | -258.2% | ||
| Q3 25 | — | -226.9% | ||
| Q2 25 | 13.9% | -279.2% | ||
| Q1 25 | — | -385.0% | ||
| Q4 24 | — | -840.5% | ||
| Q3 24 | — | -305.5% | ||
| Q2 24 | — | -386.6% | ||
| Q1 24 | — | -558.3% |
净利率ABUSFHTX
| Q4 25 | — | -234.3% | ||
| Q3 25 | — | -194.4% | ||
| Q2 25 | 23.5% | -237.3% | ||
| Q1 25 | — | -316.4% | ||
| Q4 24 | — | -682.9% | ||
| Q3 24 | — | -244.9% | ||
| Q2 24 | — | -333.6% | ||
| Q1 24 | — | -495.4% |
每股收益（稀释后）ABUSFHTX
| Q4 25 | — | $-0.35 | ||
| Q3 25 | — | $-0.25 | ||
| Q2 25 | $0.01 | $-0.28 | ||
| Q1 25 | — | $-0.30 | ||
| Q4 24 | — | $-0.23 | ||
| Q3 24 | — | $-0.31 | ||
| Q2 24 | — | $-0.45 | ||
| Q1 24 | — | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $37.4M | $80.9M |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $83.0M | $-108.5M |
| 总资产 | $103.3M | $198.1M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资ABUSFHTX
| Q4 25 | — | $80.9M | ||
| Q3 25 | — | $89.3M | ||
| Q2 25 | $37.4M | $72.6M | ||
| Q1 25 | — | $61.0M | ||
| Q4 24 | — | $55.5M | ||
| Q3 24 | — | $57.7M | ||
| Q2 24 | — | $138.9M | ||
| Q1 24 | — | $79.3M |
总债务ABUSFHTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABUSFHTX
| Q4 25 | — | $-108.5M | ||
| Q3 25 | — | $-89.7M | ||
| Q2 25 | $83.0M | $-76.7M | ||
| Q1 25 | — | $-61.7M | ||
| Q4 24 | — | $-45.5M | ||
| Q3 24 | — | $-28.3M | ||
| Q2 24 | — | $-14.3M | ||
| Q1 24 | — | $-97.5M |
总资产ABUSFHTX
| Q4 25 | — | $198.1M | ||
| Q3 25 | — | $205.0M | ||
| Q2 25 | $103.3M | $226.2M | ||
| Q1 25 | — | $258.7M | ||
| Q4 24 | — | $284.0M | ||
| Q3 24 | — | $308.4M | ||
| Q2 24 | — | $328.6M | ||
| Q1 24 | — | $255.0M |
负债/权益比ABUSFHTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.7M | $-22.3M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | -6.24× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ABUSFHTX
| Q4 25 | — | $-22.3M | ||
| Q3 25 | — | $-18.9M | ||
| Q2 25 | $-15.7M | $-21.0M | ||
| Q1 25 | — | $-24.0M | ||
| Q4 24 | — | $-24.5M | ||
| Q3 24 | — | $-21.0M | ||
| Q2 24 | — | $-25.5M | ||
| Q1 24 | — | $-29.3M |
自由现金流ABUSFHTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-21.0M | ||
| Q1 25 | — | $-24.0M | ||
| Q4 24 | — | $-25.0M | ||
| Q3 24 | — | $-21.3M | ||
| Q2 24 | — | $-25.6M | ||
| Q1 24 | — | $-29.4M |
自由现金流率ABUSFHTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -278.2% | ||
| Q1 25 | — | -403.2% | ||
| Q4 24 | — | -875.3% | ||
| Q3 24 | — | -273.0% | ||
| Q2 24 | — | -371.0% | ||
| Q1 24 | — | -583.1% |
资本支出强度ABUSFHTX
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 2.0% |
现金转化率ABUSFHTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
